NeoGenomics

Biomarker‑informed decision‑making continues to transform lung cancer care. c‑MET CDx for NSCLC IHC testing (neogenomics.com/providers/test…) helps identify patients eligible for a new FDA‑approved targeted therapy—unlocking more personalized treatment options.

Comprehensive genomic profiling isn’t just a test—it’s a roadmap for better outcomes. Solve challenging cases with Neo Comprehensive® – Myeloid Disorders: neogenomics.com/providers/test….

Our FDA-approved companion diagnostic IHC assay helps identify patients with PTEN deficiency in metastatic hormone-sensitive prostate cancer (mHSPC) who may benefit from a new targeted therapy option. Learn more: neogenomics.com/providers/test….

Access tumor-specific genomic insights quickly and noninvasively with PanTracer LBx. Click to cover 500+ genes, from guideline-recommended to emerging alterations: neogenomics.com/providers/test….

Have a safe & happy 4th of July!

📊 MRD insights that matter. RaDaR® ST enables tracking of patient response to investigational therapies—differentiating responders from non-responders. Explore the benefits of RaDaR® ST for Pharma Partners: neogenomics.com/partners/bioph…

Dive deep with our scientific expertise: neogenomics.com/oncology-data-…. Work with one of the largest oncology reference labs in the U.S. Our deep diagnostic knowledge powers precision oncology.

PanTracer Pro ensures you have the insights tailored to your patient’s tumor type and clinical context needed to guide precision oncology: neogenomics.com/providers/onco…. #Oncology #PanTracerPro #NeoGenomics #CancerTesting

From forecasting to diagnostic trend analysis, we deliver data solutions tailored to your product goals and timelines: neogenomics.com/oncology-data-…. #Oncology #OncologyData

Accurate risk stratification starts with the right test. Neo Comprehensive® – Myeloid Disorders delivers precision for myeloid disorders, including MDS and CMML: neogenomics.com/providers/test… Better data, better care.

NeoGenomics is pleased to offer the PD-L1 22C3 FDA for Ovarian Carcinoma assay with a rapid 2-day turnaround time (TAT) to support timely patient care and clinical decision-making: neogenomics.com/providers/test…. #OvarianCancer #Oncology #CancerTesting

The c‑MET CDx for NSCLC IHC assay is available to support precision oncology for patients with EGFR wild‑type NSCLC: neogenomics.com/providers/test… And, this IHC assay detects HGF Receptor (c-Met) protein expression and integrates seamlessly into PanTracer Tissue workflows.

TSO500 delivers the molecular clarity biopharma teams need across the therapeutic development — from biomarker discovery to resistance detection, trial enrollment, longitudinal monitoring, and patient stratification: neogenomics.com/tso500.

Our digital #pathology library is rich with real clinical context—built to support your AI models and fuel discovery. Let’s talk image-powered research: neogenomics.com/oncology-data-…. #DigitalPathology #AIinOncology #NeoGenomics

When cancer leaves only a trace… can you still detect it? Join us for a #webinar with Basem Goueli, MD, PhD, MBA, as he explores how RaDaR® ST is advancing MRD detection down to 1 part per million (ppm): #9pnd-1959693=calendar_1117919_3upcoming&lct=conferencecenter" target="_blank" rel="nofollow noopener">engagez.net/neowebinar16#9….

During #CancerSurvivor Month, we’re recognizing the importance of tools informed by science. RaDaR® ST is supported by an expanding base of clinical evidence, contributing to continued learning in cancer care and survivorship. Learn more: neogenomics.com/providers/onco…

Register for Liquid Biopsy: Advancing Precision Care in Oncology 🔗 engagez.net/neowebinar15. This #webinar will explore how a minimally invasive approach can complement tissue testing & improve patient outcomes through faster, more personalized treatment decisions.

The NEO AML Express assay offers class-leading turnaround times, a single report that provides a comprehensive NGS-based assessment, and rapid diagnostic, prognostic, and therapeutic information to inform personalized treatment decisions: neogenomics.com/providers/test….

RaDaR® ST offers a streamlined workflow for actionable insights, helping pharma partners monitor therapeutic response with precision. See how it works: neogenomics.com/partners/bioph…

#ASCO26 just wrapped up! We had the chance to connect with so many people & discuss how we can work together to advance personalized cancer care across the care continuum. If we didn’t get to meet, or you’d like to continue the discussion, let's connect: mailchi.mp/neogenomics/as….